Anika Therapeutics (NASDAQ:ANIK - Get Free Report) is projected to announce its earnings results after the market closes on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $29.00 million for the quarter. Investors that wish to register for the company's conference call can do so using this link.
Anika Therapeutics Stock Performance
Shares of ANIK stock traded down $0.38 on Friday, hitting $16.62. The stock had a trading volume of 97,750 shares, compared to its average volume of 65,387. Anika Therapeutics has a 52-week low of $15.40 and a 52-week high of $29.11. The firm has a market capitalization of $243.42 million, a price-to-earnings ratio of -2.50 and a beta of 0.95. The stock's 50 day moving average is $16.90 and its 200-day moving average is $19.87.
Anika Therapeutics Company Profile
(
Get Free Report)
Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
Recommended Stories
Before you consider Anika Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anika Therapeutics wasn't on the list.
While Anika Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
